This drug (Bremelanotide) is based on Melanotan II, an injectable, non-selective melanocortin receptor agonist that chemically induces skin tanning. Melanotan II has the added effect of increasing libido.
en.wikipedia.org/wiki/Melanotan
biopsychiatry.com/melanotan.htm
However, Melanotan II safety has not been reviewed by the FDA and thus there are warnings about it. It is in fact, illegal: fda.gov/consumer/updates/mel … 90507.html
lookingfit.com/hotnews/79h119325.html
I am not advocating anyone take this compound. The FDA cautions consumers about injecting any substance, particularly products that are not FDA-approved, into their bodies without consulting a licensed healthcare provider. The above is just background info on Melanotan II, as it is the basis for Bremelanotide, the drug being developed for treatment of libido loss (below).
Bremelanotide – developed by Palatin Technologies: palatin.com/products/bremela … erview.asp
From en.wikipedia.org/wiki/Bremelanotide:
Bremelanotide (formerly PT-141) is the generic term for a new medication for use in treating sexual dysfunction in men (erectile dysfunction or impotence) as well as sexual dysfunction in women (sexual arousal disorder). It is the only known synthetic aphrodisiac. Unlike Viagra and other related medications, it does not act upon the vascular system, but directly increases sexual desire. Bremelanotide is a spray introduced nasally.
Originally, the peptide Melanotan II that bremelanotide was developed from was tested as a sunless tanning agent. In initial testing, Melanotan II did induce tanning but additionally caused sexual arousal and spontaneous erections as unexpected side effects in nine out of the ten original male volunteer test subjects.[1] In clinical studies, bremelanotide has been shown to be effective in treating male sexual and erectile dysfunction as well as female sexual dysfunction. It is currently being tested by Palatin Technologies.
A Phase III clinical trial was scheduled to begin in the first half of 2007, but was delayed until August 2007. On August 30th, Palatin announced that the FDA had expressed serious concerns regarding the benefit/risk ratio of bremelanotide with regards to the side effect of increased blood pressure. The FDA also stated that they would consider alternate uses for bremelanotide, including as a treatment for individuals who do not respond to more established ED treatments.